S.S. Ramalingam

机构：Emory University, Piedmont Cancer Institute

发表论文 6 篇 · 总被引 22 次 · h-index 2

代表论文

OA14.03 Six-year Survival and HRQoL Outcomes with 1L Nivolumab + Ipilimumab in Patients with Metastatic NSCLC from CheckMate227 (2023 · Journal of Thoracic Oncology · 被引 12)
PL03.06 EA5181: Phase 3 Trial of Concurrent and Consolidative Durvalumab vs Consolidation Durva Alone for Unresectable Stage 3 NSCLC (2025 · Journal of Thoracic Oncology · 被引 9)
LBA104 Primary results of DREAM3R: DuRvalumab (MEDI4736) with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma: A phase III randomised trial (2025 · Annals of Oncology · 被引 1)
MO1-1 6y update of 1L nivolumab + ipilimumab (N+I) in metastatic (m) NSCLC, including in Japanese pts, from CheckMate 227 (2024 · Annals of Oncology)
41P Efficacy of first-line (1L) nivolumab (N) + ipilimumab (I) by tumor histologic subtype in patients (pts) with metastatic nonsquamous NSCLC (mNSQ-NSCLC) (2023 · Journal of Thoracic Oncology)
PPD04.02 First-Line Nivolumab + Ipilimumab (NIVO+IPI) in Metastatic NSCLC: 5-Year Survival in CheckMate 227 (2023 · Journal of Thoracic Oncology)